Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Forest Laboratories
With
AstraZeneca
To evaluate safety, effectiveness, pharmacokinetics and tolerance of Ceftaroline fosamil in children who are initially hospitalized with Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
Age
0–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female, 2 months to \< 18 years old.
Presence of ABSSSI warranting initial hospitalization.
Presence of ABSSSI with measurable margins of erythema, that includes deeper and/or extensive soft tissue involvement, or requires significant therapeutic surgical intervention
You may not be if
Documented history of any hypersensitivity or allergic reaction to vancomycin, aztreonam, or any β-lactam antimicrobial
Uncomplicated skin and soft tissue infections
More than 24 hours of prior antimicrobial therapy ≤ 96 hours before randomization.
Requirement for any concomitant systemic antimicrobial therapy
History of seizures, excluding well-documented febrile seizure of childhood.
